Navamedic ASA appoints new CEO
(Thomson Reuters ONE) -
Tom Rönnlund has been appointed new CEO of Navamedic ASA. Mr Rönnlund brings
more than 17 years of business development and general management experience
from the international healthcare industry to Navamedic.
Tom Rönnlund joins Navamedic from IMS Health Inc, a global analytics and
technology services company focused on the healthcare sector, where he held the
position of General Manager for the Nordic & Baltic Region. Prior to joining IMS
Health, Tom has served in sales, marketing and general management roles with
biopharmaceutical companies such as Bristol-Myers Squibb and Eli Lilly. He holds
a degree in Business Administration and Economics from Stockholm University.
Tom Rönnlund assumes his new responsibilities at Navamedic on 18 May 2015.
"We are pleased that we have succeeded in recruiting Tom Rönnlund to Navamedic.
He brings with him vast industry experience from Nordic and international
markets and an impressive track record of business growth and general managemet.
I am confident he will succeed in reinforcing the positive revenue and profit
development the company is experiencing together with the Navamedic team. We
thank Håkan Josephsson, who remains with the company, for his invaluable support
as interim CEO" Navamedic Chairman Johan Reinsli said.
"I am very excited to join Navamedic and am looking forward to build on the
great work by the current management team in focusing the product portfolio for
continued growth and improved profitability as well as actively pursue portfolio
expansion through partnerships and potential acquisitions" says Tom Rönnlund
For further information, please contact Navamedic's Chairman Johan Reinsli,
telephone +47 91604145 or Tom Rönnlund, appointed CEO, telephone
+46 768 564 735.
Navamedic ASA is a Norwegian pharmaceutical products company, marketing and
distributing more than 120 products in the Nordic and Benelux markets. The
Company operates three business areas; Pharma Products, Medical Nutrition and
Consumer Care based on its relationship with a number of pharmaceutical product
manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Navamedic ASA via GlobeNewswire
[HUG#1914030]
Unternehmensinformation / Kurzprofil:
Datum: 23.04.2015 - 15:19 Uhr
Sprache: Deutsch
News-ID 388106
Anzahl Zeichen: 3114
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Navamedic ASA appoints new CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
